News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EMD Group (EMD Millipore Headquarters) And Massachusetts General Hospital Collaborate To Better Understand Systemic Lupus Erythematosus And Lupus Nephritis



9/2/2014 11:25:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BILLERICA, Mass.--(BUSINESS WIRE)--EMD Serono Research and Development Institute, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, entered into a collaborative research agreement with Massachusetts General Hospital (MGH) to further the understanding of Systemic Lupus Erythematosus and Lupus Nephritis pathogenesis.

Systemic Lupus Erythematosus (SLE) is an autoimmune disease, where the immune system produces proteins called autoantibodies that attack patients’ own tissues and organs. According to the Lupus Foundation of America, approximately 1.5 million Americans have SLE. Up to 60% of patients with SLE develop inflammation in the kidneys known as Lupus Nephritis (LN), which if uncontrolled can lead to kidney failure. SLE and LN represent an area of high unmet medical need, where new therapies are vital.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES